Aktienanalyse zu Smith & Nephew PLC (SNN)SNNSmith & Nephew PLC

Smith & Nephew plc is a portfolio medical technology company. The Company is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, which includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilize severe fractures and correct bone deformities; Sports Medicine & ENT businesses offer advanced products and instruments used to repair or remove soft tissue, and Advanced Wound Management provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds. The Company also owns Integrity Orthopaedics, which is an early stage commercial developer of Tendon Seam, an innovative and disruptive biomechanical RCR system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

Smith & Nephew PLC (SNN) is currently priced at $27.24, with a forward P/E of 11.16, indicating it is relatively undervalued compared to its earnings potential. However, the stock has a year-to-date change of -17.15%, suggesting ongoing challenges. The RSI is at 62, indicating the stock is nearing overbought territory. The main risk is the significant insider selling, which has increased by 225.80% over the last quarter, suggesting a lack of confidence among insiders.

4 analysts cover SNN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 35.75.